Home  »  Trending   »  Acorda Therapeutics Inc. (ACOR) Downgrade Issued b...

Acorda Therapeutics Inc. (ACOR) Downgrade Issued by Wall Street Gurus

Acorda Therapeutics Inc. (NASDAQ:ACOR) went down by -7.39% from its latest closing price compared to the recent 1-year high of $6.36. The company’s stock price has collected -23.62% of loss in the last five trading sessions.

Is It Worth Investing in Acorda Therapeutics Inc. (NASDAQ :ACOR) Right Now?

Plus, the 36-month beta value for ACOR is at 0.38. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Acorda Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $10.00. ACOR currently public float of 13.11M and currently shorts hold a 11.04% ratio of that float. Today, the average trading volume of ACOR was 1.66M shares.

ACOR’s Market Performance

ACOR stocks went down by -23.62% for the week, with a monthly jump of 18.29% and a quarterly performance of -72.13%, while its annual performance rate touched -90.66%. The volatility ratio for the week stands at 19.07% while the volatility levels for the past 30 days are set at 21.59% for Acorda Therapeutics Inc. The simple moving average for the period of the last 20 days is 10.47% for ACOR stocks with a simple moving average of -79.33% for the last 200 days.

Analysts’ Opinion of ACOR

Many brokerage firms have already submitted their reports for ACOR stocks, with H.C. Wainwright repeating the rating for ACOR by listing it as a “Buy.” The predicted price for ACOR in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on June 17th of the previous year 2021.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see ACOR reach a price target of $6, previously predicting the price at $31. The rating they have provided for ACOR stocks is “Neutral” according to the report published on August 14th, 2019.

ACOR Trading at -39.58% from the 50-Day Moving Average

After a stumble in the market that brought ACOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.37% of loss for the given period.

Volatility was left at 21.59%, however, over the last 30 days, the volatility rate increased by 19.07%, as shares surge +17.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -69.50% lower at present.

During the last 5 trading sessions, ACOR fell by -23.62%, which changed the moving average for the period of 200-days by -89.13% in comparison to the 20-day moving average, which settled at $0.4426. In addition, Acorda Therapeutics Inc. saw -79.71% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ACOR starting from COHEN RON, who sale 2,289 shares at the price of $1.70 back on Mar 17. After this action, COHEN RON now owns 129,601 shares of Acorda Therapeutics Inc., valued at $3,895 using the latest closing price.

Stock Fundamentals for ACOR

Current profitability levels for the company are sitting at:

  • -55.24 for the present operating margin
  • +44.56 for the gross margin

The net margin for Acorda Therapeutics Inc. stands at -80.54. Equity return is now at value -60.00, with -20.70 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 1.89.